Table 4, Patient Risk Factors and Clinical Tests Used to Identify Study Populations at Increased Risk for Preeclampsia - Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Henderson JT, Vesco KK, Senger CA, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. (Evidence Synthesis, No. 205.)

Cover of Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality

Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality [Internet].

Show details

Contents

Table 4Patient Risk Factors and Clinical Tests Used to Identify Study Populations at Increased Risk for Preeclampsia

Author, Year	%Preeclampsia incidence in control group	Hx of preeclampsia or hypertension^*	Maternal Age	Nulliparity	Multifetal gestation	Renal Disease	Metabolic disease	Hx of Stillbirth	Hx spontaneous abortion	Hx of SGA/IUGR	Diabetes	Prediction model^†	Hemoglobin concentration	Positive rollover test	Angiotensin-II sensitivity	Abnormal Doppler readings
Benigni, 1989⁸⁸	NR	x						x		x
Gallery, 1997⁹⁷	NR	x				x
Scazzocchio, 2017^‡¹⁰⁶	4															x
CLASP, 1994⁹⁵	8	x	x		x	x
Caspi, 1994⁹⁴	9				x
Grab, 2000¹⁰¹	10	x						x		x
ASPRE, 2017⁵⁹	11	X										x				X
Viinikka, 1993⁹³	11	x
Davies, 1995⁹⁶	12			x^§									x
Ayala, 2012⁵⁷	13	x	x	x	x		x		x
Hermida, 1997⁹⁸	14	x	x	x	x		x		x
Villa, 2012¹⁰⁴	18	x							x	x	x					x
McParland, 1990⁹⁰	19			x^§												x
Yu, 2003^ǁ¹⁰³	19															x
MFMU-HR, 1998⁹⁹	20	x			x						x
Morris, 1996¹⁰⁷	14			x												x
Schiff, 1989⁸⁹	23	x		x	x									x
Wallenburg, 1986⁸⁷	30			x^§											x

: Abbreviations: Hx = History; SGA/IUGR = Small for gestational age/intrauterine growth restriction; NR = Not reported
*: Includes personal history of gestational hypertension, chronic hypertension, or preeclampsia
†: Prediction model includes maternal risk factors, serum biomarkers, Doppler ultrasound
‡: Excluded individuals with a multifetal gestation or history of preeclampsia, hypertension, renal disease, or cardiovascular disease.
§: Population limited to nulliparous individuals
ǁ: Excluded criteria included individuals with history of hypertensive disease, renal and cardiovascular disease, and diabetes.

From: Chapter 3, Results

Contents

Views

Cite this Page
Henderson JT, Vesco KK, Senger CA, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. (Evidence Synthesis, No. 205.) Table 4, Patient Risk Factors and Clinical Tests Used to Identify Study Populations at Increased Risk for Preeclampsia.
PDF version of this title (2.3M)

Other titles in this collection

U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews

Recent Activity

Clear Turn Off Turn On

Table 4, Patient Risk Factors and Clinical Tests Used to Identify Study Populati...
Table 4, Patient Risk Factors and Clinical Tests Used to Identify Study Populations at Increased Risk for Preeclampsia - Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality
PREDICTED: Homo sapiens STEAP3 metalloreductase (STEAP3), transcript variant X1,...
PREDICTED: Homo sapiens STEAP3 metalloreductase (STEAP3), transcript variant X1, mRNA
gi|767918678|ref|XM_011511403.1|
Nucleotide
Virtual Clinical Trials
Virtual Clinical Trials

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on